<DOC>
	<DOC>NCT01157104</DOC>
	<brief_summary>This study is designed to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction between IDX320 and IDX184 and to assess the safety and tolerability when the two drugs are administered in combination in healthy participants.</brief_summary>
	<brief_title>A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>To participate in the study, participants must meet the following requirements: 1. Must be a healthy male or female between 19 and 65 years of age with body mass index (BMI) between 18 and 35 kg/m2. 2. Must be a nonsmoker. 3. Must agree to use an acceptable doublebarrier method of birth control. 4. Must provide written informed consent after the study has been fully explained. Participants are not eligible if they meet any of the following: 1. Pregnant or breastfeeding. 2. History of clinically significant diseases, as determined by the investigator. 3. Safety laboratory abnormalities at screening which are clinically significant. 4. Positive screening test for hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV). 5. Use of chronic prescription medications within 3 months, acute prescription medications within 14 days, or systemic overthecounter (OTC) medications within 7 days of the starting the study. 6. Current abuse of alcohol or illicit drugs, or history of alcohol or illicit drug abuse within the preceding two years.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>